Zhejiang Garden BiopharmaceuticalLtd Balance Sheet Health
Financial Health criteria checks 4/6
Zhejiang Garden BiopharmaceuticalLtd has a total shareholder equity of CN¥3.1B and total debt of CN¥1.7B, which brings its debt-to-equity ratio to 55.6%. Its total assets and total liabilities are CN¥5.5B and CN¥2.4B respectively. Zhejiang Garden BiopharmaceuticalLtd's EBIT is CN¥256.8M making its interest coverage ratio 12. It has cash and short-term investments of CN¥1.4B.
Key information
55.6%
Debt to equity ratio
CN¥1.75b
Debt
| Interest coverage ratio | 12x |
| Cash | CN¥1.43b |
| Equity | CN¥3.14b |
| Total liabilities | CN¥2.39b |
| Total assets | CN¥5.53b |
Recent financial health updates
Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Sep 29
Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?
May 31Recent updates
Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Profits May Not Reveal Underlying Issues
Oct 24Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) Has A Somewhat Strained Balance Sheet
Sep 29Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) Stock Retreats 26% But Earnings Haven't Escaped The Attention Of Investors
Sep 08Why Investors Shouldn't Be Surprised By Zhejiang Garden Biopharmaceutical Co.,Ltd.'s (SZSE:300401) 27% Share Price Surge
Jun 30Is Zhejiang Garden BiopharmaceuticalLtd (SZSE:300401) A Risky Investment?
May 31Subdued Growth No Barrier To Zhejiang Garden Biopharmaceutical Co.,Ltd. (SZSE:300401) With Shares Advancing 27%
May 06Why Zhejiang Garden BiopharmaceuticalLtd's (SZSE:300401) Shaky Earnings Are Just The Beginning Of Its Problems
Apr 22Financial Position Analysis
Short Term Liabilities: 300401's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥1.2B).
Long Term Liabilities: 300401's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥1.2B).
Debt to Equity History and Analysis
Debt Level: 300401's net debt to equity ratio (10.1%) is considered satisfactory.
Reducing Debt: 300401's debt to equity ratio has increased from 8.8% to 55.6% over the past 5 years.
Debt Coverage: 300401's debt is not well covered by operating cash flow (18.8%).
Interest Coverage: 300401's interest payments on its debt are well covered by EBIT (12x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 19:55 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Zhejiang Garden Biopharmaceutical Co.,Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Zhe Wang | Citic Securities Co., Ltd. |
| Wei Liu | Haitong International Research Limited |
| Song Yang | Tianfeng Securities Brokerage Co., Ltd |